English

Bellicum Pharmaceuticals, Inc.

EDGAR

BLCM Current report (8-K) · filed 2024-02-21

78 filing records in this dataset, filed from 2014-11-18 to 2024-02-21. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

1 million USD

2023 Q3 · USD

Exact inputs and evidence

Revenue: 1000000 USD Source

Operating margin

-77.3%

2023 Q3 · %

Exact inputs and evidence

Operating Income: -773000 USD Source
Revenue: 1000000 USD Source

Operating cash flow

-1.52 million USD

2023 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -15939000 USD Source
Operating Cash Flow: -14423000 USD Source

Free cash flow

-1.52 million USD

2023 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -15939000 USD Source
Operating Cash Flow: -14423000 USD Source
Capital Expenditure: 4000 USD Source
Capital Expenditure: 4000 USD Source

Cash and cash equivalents: 5.9 million USD 2023-09-30 Source
Exact value

5900000 USD
Long-term debt including current maturities: 28.5 million USD 2019-09-30 Source
Exact value

28494000 USD
Shares outstanding: 9.72 million shares 2023-09-30 Source
Exact value

9716931 shares

Reported share-count change

12.82% · 1.1 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

8612941 shares · 2022-09-30· Source
9716931 shares · 2023-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

1.51 million USD

2022-10-01 – 2023-09-30

Exact inputs and evidence

Revenue: 1500000 USD · 2022-01-01 – 2022-12-31 Source
Revenue: 1000000 USD · 2022-01-01 – 2022-09-30 Source
Revenue: 8000 USD · 2023-01-01 – 2023-03-31 Source
Revenue: 0 USD · 2023-04-01 – 2023-06-30 Source
Revenue: 1000000 USD · 2023-07-01 – 2023-09-30 Source

Net income

-22.4 million USD

2022-10-01 – 2023-09-30

Exact inputs and evidence

Net income: -24973000 USD · 2022-01-01 – 2022-12-31 Source
Net income: -18776000 USD · 2022-01-01 – 2022-09-30 Source
Net income: -8066000 USD · 2023-01-01 – 2023-03-31 Source
Net income: -7352000 USD · 2023-04-01 – 2023-06-30 Source
Net income: -763000 USD · 2023-07-01 – 2023-09-30 Source

Operating cash flow

-22.9 million USD

2022-10-01 – 2023-09-30

Exact inputs and evidence

Operating cash flow: -25783000 USD · 2022-01-01 – 2022-12-31 Source
Operating cash flow: -18872000 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -6430000 USD · 2023-01-01 – 2023-03-31 Source
Operating cash flow: -14423000 USD · 2023-01-01 – 2023-06-30 Source
Operating cash flow: -6430000 USD · 2023-01-01 – 2023-03-31 Source
Operating cash flow: -15939000 USD · 2023-01-01 – 2023-09-30 Source
Operating cash flow: -14423000 USD · 2023-01-01 – 2023-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2024-02-21.

Financial data available through: 2022-12-31.

Coverage by financial measure

Revenue: 10 of 11 periods available· newest 2022-12-31
Operating income: 10 of 11 periods available· newest 2022-12-31
Net income: 10 of 11 periods available· newest 2022-12-31
Operating cash flow: 10 of 11 periods available· newest 2022-12-31
Capital expenditure: 10 of 11 periods available· newest 2022-12-31
Total assets: 9 of 11 periods available· newest 2022-12-31
Total liabilities: 9 of 11 periods available· newest 2022-12-31
Current assets: 9 of 11 periods available· newest 2022-12-31
Current liabilities: 9 of 11 periods available· newest 2022-12-31
Cash and cash equivalents: 10 of 11 periods available· newest 2022-12-31
Long-term debt including current maturities: 4 of 11 periods available· newest 2018-12-31
Shares outstanding: 9 of 11 periods available· newest 2022-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-75.8%

Prior period

USD 6.2 million

2021-01-01 – 2021-12-31
Current period

USD 1.5 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

1500000 − 6200000 = -4700000 USD

6200000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
1500000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Bellicum Pharmaceuticals, Inc. · 2022-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Year-over-year change in Revenue: -4700000 USD Concept: fundies:Revenue Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 1500000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000162828023010145/blcm-20221231.htm#668261 Filing: 000162828023010145 Input fundies:Revenue: 6200000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000162828023010145/blcm-20221231.htm#668984 Filing: 000162828023010145
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 15.27 million

Prior period

−USD 9.71 million

2021-01-01 – 2021-12-31
Current period

−USD 24.97 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-24973000 − -9705000 = -15268000 USD

-9705000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-24973000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Bellicum Pharmaceuticals, Inc. · 2022-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Year-over-year change in Net income: -15268000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -24973000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000162828023010145/blcm-20221231.htm#791605 Filing: 000162828023010145 Input fundies:NetIncome: -9705000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000162828023010145/blcm-20221231.htm#792443 Filing: 000162828023010145
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 2.68 million

Prior period

−USD 23.11 million

2021-01-01 – 2021-12-31
Current period

−USD 25.78 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-25783000 − -23106000 = -2677000 USD

-23106000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-25783000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Bellicum Pharmaceuticals, Inc. · 2022-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Year-over-year change in Operating cash flow: -2677000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -25783000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000162828023010145/blcm-20221231.htm#810046 Filing: 000162828023010145 Input fundies:OperatingCashFlow: -23106000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000162828023010145/blcm-20221231.htm#810765 Filing: 000162828023010145
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+200%

Prior period

USD 7,000

2021-01-01 – 2021-12-31
Current period

USD 21,000

2022-01-01 – 2022-12-31

Exact inputs and evidence

21000 − 7000 = 14000 USD

7000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
21000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Bellicum Pharmaceuticals, Inc. · 2022-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Year-over-year change in Capital expenditure: 14000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 21000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000162828023010145/blcm-20221231.htm#813863 Filing: 000162828023010145 Input fundies:CapitalExpenditure: 7000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000162828023010145/blcm-20221231.htm#814482 Filing: 000162828023010145
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2022 2022-01-01 – 2022-12-31

Revenue USD 1.5 million 100% of revenue
Operating costs Derived USD 28.48 million 1,899% of revenue
Operating income −USD 26.98 million −1,799% of revenue
Tax, interest and other Derived −USD 2.01 million −134% of revenue
Net income −USD 24.97 million −1,665% of revenue

Cash

Operating cash flow −USD 25.78 million −1,719% of revenue
Capital expenditure USD 21,000 1.4% of revenue
Free cash flow Derived −USD 25.8 million −1,720% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2013 Operating loss: operating costs were 508% of revenue.
2014 Operating loss: operating costs were 3,349% of revenue.
2015 Operating loss: operating costs were 17,524% of revenue.
2016 Operating loss: operating costs were 17,724% of revenue.
2017 Operating loss: operating costs were 47,336% of revenue.
2018 Operating loss: operating costs were 8,624% of revenue.
2019 Operating loss: operating costs were 1,323% of revenue.
2020 Operating loss: operating costs were 10,438% of revenue.
2021 Operating loss: operating costs were 501% of revenue.
2022 Operating loss: operating costs were 1,899% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2013 2013-01-01 – 2013-12-31	1941000	9863000 Derived	-7922000	47000 Derived	-7969000	-7978000 Derived	Source 2013-01-01 – 2013-12-31: 1941000 USD Inspect Revenue Open source 2013-01-01 – 2013-12-31: -7922000 USD Inspect Operating Income Open source 2013-01-01 – 2013-12-31: -7969000 USD Inspect Net Income Open source 2013-01-01 – 2013-12-31: -7612000 USD Inspect Operating Cash Flow Open source 2013-01-01 – 2013-12-31: 366000 USD Inspect Capital Expenditure Open source
2014 2014-01-01 – 2014-12-31	1780000	59618000 Derived	-57838000	26127000 Derived	-83965000	-58112000 Derived	Source 2014-01-01 – 2014-12-31: 1780000 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: -57838000 USD Inspect Operating Income Open source 2014-01-01 – 2014-12-31: -83965000 USD Inspect Net Income Open source 2014-01-01 – 2014-12-31: -57308000 USD Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 804000 USD Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	282000	49417000 Derived	-49135000	-587000 Derived	-48548000	-41147000 Derived	Source 2015-01-01 – 2015-12-31: 282000 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -49135000 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -48548000 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: -35726000 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 5421000 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	388000	68768000 Derived	-68380000	861000 Derived	-69241000	-57661000 Derived	Source 2016-01-01 – 2016-12-31: 388000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -68380000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -69241000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -50441000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 7220000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	185000	87572000 Derived	-87387000	4392000 Derived	-91779000	-85118000 Derived	Source 2017-01-01 – 2017-12-31: 185000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -87387000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -91779000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -72984000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 12134000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	1120000	96586000 Derived	-95466000	2570000 Derived	-98036000	-76399000 Derived	Source 2018-01-01 – 2018-12-31: 1120000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -95466000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -98036000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -74782000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 1617000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	7143000	94507000 Derived	-87364000	25113000 Derived	-112477000	-78091000 Derived	Source 2019-01-01 – 2019-12-31: 7143000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -87364000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -112477000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -77569000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 522000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	500000	52192000 Derived	-51692000	-43970000 Derived	-7722000	-57275000 Derived	Source 2020-01-01 – 2020-12-31: 500000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -51692000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -7722000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -56650000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 625000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	6200000	31066000 Derived	-24866000	-15161000 Derived	-9705000	-23113000 Derived	Source 2021-01-01 – 2021-12-31: 6200000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -24866000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -9705000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -23106000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 7000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	1500000	28481000 Derived	-26981000	-2008000 Derived	-24973000	-25804000 Derived	Source 2022-01-01 – 2022-12-31: 1500000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -26981000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -24973000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -25783000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 21000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 1.5M 2022

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20132013-12-31	Revenue	1941000	Revenue: 1941000 Open source
20142014-12-31	Revenue	1780000	Revenue: 1780000 Open source
20152015-12-31	Revenue	282000	Revenue: 282000 Open source
20162016-12-31	Revenue	388000	Revenue: 388000 Open source
20172017-12-31	Revenue	185000	Revenue: 185000 Open source
20182018-12-31	Revenue	1120000	Revenue: 1120000 Open source
20192019-12-31	Revenue	7143000	Revenue: 7143000 Open source
20202020-12-31	Revenue	500000	Revenue: 500000 Open source
20212021-12-31	Revenue	6200000	Revenue: 6200000 Open source
20222022-12-31	Revenue	1500000	Revenue: 1500000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-75.8% 2022

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20132013-12-31	Year over year	No prior comparable period	Revenue: 1941000 Open source
20142014-12-31	Year over year	-8.3%	Revenue: 1780000 Open source Revenue: 1941000 Open source
20152015-12-31	Year over year	-84.2%	Revenue: 282000 Open source Revenue: 1780000 Open source
20162016-12-31	Year over year	37.6%	Revenue: 388000 Open source Revenue: 282000 Open source
20172017-12-31	Year over year	-52.3%	Revenue: 185000 Open source Revenue: 388000 Open source
20182018-12-31	Year over year	505.4%	Revenue: 1120000 Open source Revenue: 185000 Open source
20192019-12-31	Year over year	537.8%	Revenue: 7143000 Open source Revenue: 1120000 Open source
20202020-12-31	Year over year	-93%	Revenue: 500000 Open source Revenue: 7143000 Open source
20212021-12-31	Year over year	1,140%	Revenue: 6200000 Open source Revenue: 500000 Open source
20222022-12-31	Year over year	-75.8%	Revenue: 1500000 Open source Revenue: 6200000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -1,798.7% 2022

Net margin -1,664.9% 2022

Free cash flow margin -1,720.3% 2022

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20132013-12-31	Operating margin	-408.1%	Operating Income: -7922000 Open source Revenue: 1941000 Open source
20142014-12-31	Operating margin	-3,249.3%	Operating Income: -57838000 Open source Revenue: 1780000 Open source
20152015-12-31	Operating margin	-17,423.8%	Operating Income: -49135000 Open source Revenue: 282000 Open source
20162016-12-31	Operating margin	-17,623.7%	Operating Income: -68380000 Open source Revenue: 388000 Open source
20172017-12-31	Operating margin	-47,236.2%	Operating Income: -87387000 Open source Revenue: 185000 Open source
20182018-12-31	Operating margin	-8,523.8%	Operating Income: -95466000 Open source Revenue: 1120000 Open source
20192019-12-31	Operating margin	-1,223.1%	Operating Income: -87364000 Open source Revenue: 7143000 Open source
20202020-12-31	Operating margin	-10,338.4%	Operating Income: -51692000 Open source Revenue: 500000 Open source
20212021-12-31	Operating margin	-401.1%	Operating Income: -24866000 Open source Revenue: 6200000 Open source
20222022-12-31	Operating margin	-1,798.7%	Operating Income: -26981000 Open source Revenue: 1500000 Open source
20132013-12-31	Net margin	-410.6%	Net Income: -7969000 Open source Revenue: 1941000 Open source
20142014-12-31	Net margin	-4,717.1%	Net Income: -83965000 Open source Revenue: 1780000 Open source
20152015-12-31	Net margin	-17,215.6%	Net Income: -48548000 Open source Revenue: 282000 Open source
20162016-12-31	Net margin	-17,845.6%	Net Income: -69241000 Open source Revenue: 388000 Open source
20172017-12-31	Net margin	-49,610.3%	Net Income: -91779000 Open source Revenue: 185000 Open source
20182018-12-31	Net margin	-8,753.2%	Net Income: -98036000 Open source Revenue: 1120000 Open source
20192019-12-31	Net margin	-1,574.6%	Net Income: -112477000 Open source Revenue: 7143000 Open source
20202020-12-31	Net margin	-1,544.4%	Net Income: -7722000 Open source Revenue: 500000 Open source
20212021-12-31	Net margin	-156.5%	Net Income: -9705000 Open source Revenue: 6200000 Open source
20222022-12-31	Net margin	-1,664.9%	Net Income: -24973000 Open source Revenue: 1500000 Open source
20132013-12-31	Free cash flow margin	-411%	Revenue: 1941000 Open source Operating Cash Flow: -7612000 Open source Capital Expenditure: 366000 Open source
20142014-12-31	Free cash flow margin	-3,264.7%	Revenue: 1780000 Open source Operating Cash Flow: -57308000 Open source Capital Expenditure: 804000 Open source
20152015-12-31	Free cash flow margin	-14,591.1%	Revenue: 282000 Open source Operating Cash Flow: -35726000 Open source Capital Expenditure: 5421000 Open source
20162016-12-31	Free cash flow margin	-14,861.1%	Revenue: 388000 Open source Operating Cash Flow: -50441000 Open source Capital Expenditure: 7220000 Open source
20172017-12-31	Free cash flow margin	-46,009.7%	Revenue: 185000 Open source Operating Cash Flow: -72984000 Open source Capital Expenditure: 12134000 Open source
20182018-12-31	Free cash flow margin	-6,821.3%	Revenue: 1120000 Open source Operating Cash Flow: -74782000 Open source Capital Expenditure: 1617000 Open source
20192019-12-31	Free cash flow margin	-1,093.3%	Revenue: 7143000 Open source Operating Cash Flow: -77569000 Open source Capital Expenditure: 522000 Open source
20202020-12-31	Free cash flow margin	-11,455%	Revenue: 500000 Open source Operating Cash Flow: -56650000 Open source Capital Expenditure: 625000 Open source
20212021-12-31	Free cash flow margin	-372.8%	Revenue: 6200000 Open source Operating Cash Flow: -23106000 Open source Capital Expenditure: 7000 Open source
20222022-12-31	Free cash flow margin	-1,720.3%	Revenue: 1500000 Open source Operating Cash Flow: -25783000 Open source Capital Expenditure: 21000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -25.8M 2022

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20132013-12-31	Operating cash flow	-7612000	Operating Cash Flow: -7612000 Open source
20142014-12-31	Operating cash flow	-57308000	Operating Cash Flow: -57308000 Open source
20152015-12-31	Operating cash flow	-35726000	Operating Cash Flow: -35726000 Open source
20162016-12-31	Operating cash flow	-50441000	Operating Cash Flow: -50441000 Open source
20172017-12-31	Operating cash flow	-72984000	Operating Cash Flow: -72984000 Open source
20182018-12-31	Operating cash flow	-74782000	Operating Cash Flow: -74782000 Open source
20192019-12-31	Operating cash flow	-77569000	Operating Cash Flow: -77569000 Open source
20202020-12-31	Operating cash flow	-56650000	Operating Cash Flow: -56650000 Open source
20212021-12-31	Operating cash flow	-23106000	Operating Cash Flow: -23106000 Open source
20222022-12-31	Operating cash flow	-25783000	Operating Cash Flow: -25783000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -25.8M 2022

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20132013-12-31	Free cash flow	-7978000	Operating Cash Flow: -7612000 Open source Capital Expenditure: 366000 Open source
20142014-12-31	Free cash flow	-58112000	Operating Cash Flow: -57308000 Open source Capital Expenditure: 804000 Open source
20152015-12-31	Free cash flow	-41147000	Operating Cash Flow: -35726000 Open source Capital Expenditure: 5421000 Open source
20162016-12-31	Free cash flow	-57661000	Operating Cash Flow: -50441000 Open source Capital Expenditure: 7220000 Open source
20172017-12-31	Free cash flow	-85118000	Operating Cash Flow: -72984000 Open source Capital Expenditure: 12134000 Open source
20182018-12-31	Free cash flow	-76399000	Operating Cash Flow: -74782000 Open source Capital Expenditure: 1617000 Open source
20192019-12-31	Free cash flow	-78091000	Operating Cash Flow: -77569000 Open source Capital Expenditure: 522000 Open source
20202020-12-31	Free cash flow	-57275000	Operating Cash Flow: -56650000 Open source Capital Expenditure: 625000 Open source
20212021-12-31	Free cash flow	-23113000	Operating Cash Flow: -23106000 Open source Capital Expenditure: 7000 Open source
20222022-12-31	Free cash flow	-25804000	Operating Cash Flow: -25783000 Open source Capital Expenditure: 21000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

15.8% 2022

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2013-12-31	Liabilities / assets	Not reported	No source recorded
20142014-12-31	Liabilities / assets	2.1%	Total Liabilities: 4158000 Open source Total Assets: 195794000 Open source
20152015-12-31	Liabilities / assets	5.2%	Total Liabilities: 8389000 Open source Total Assets: 160406000 Open source
20162016-12-31	Liabilities / assets	26.9%	Total Liabilities: 35463000 Open source Total Assets: 132037000 Open source
20172017-12-31	Liabilities / assets	37.5%	Total Liabilities: 50880000 Open source Total Assets: 135528000 Open source
20182018-12-31	Liabilities / assets	43.6%	Total Liabilities: 53023000 Open source Total Assets: 121501000 Open source
20192019-12-31	Liabilities / assets	104.1%	Total Liabilities: 120999000 Open source Total Assets: 116250000 Open source
20202020-12-31	Liabilities / assets	61.7%	Total Liabilities: 25045000 Open source Total Assets: 40584000 Open source
20212021-12-31	Liabilities / assets	13.7%	Total Liabilities: 6712000 Open source Total Assets: 49143000 Open source
20222022-12-31	Liabilities / assets	15.8%	Total Liabilities: 3772000 Open source Total Assets: 23823000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

6.31× 2022

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2013-12-31	Current assets / current liabilities	Not reported	No source recorded
20142014-12-31	Current assets / current liabilities	53.14×	Current Assets: 193222000 Open source Current Liabilities: 3636000 Open source
20152015-12-31	Current assets / current liabilities	13.01×	Current Assets: 96890000 Open source Current Liabilities: 7445000 Open source
20162016-12-31	Current assets / current liabilities	6.99×	Current Assets: 105610000 Open source Current Liabilities: 15113000 Open source
20172017-12-31	Current assets / current liabilities	8.36×	Current Assets: 101650000 Open source Current Liabilities: 12156000 Open source
20182018-12-31	Current assets / current liabilities	6.03×	Current Assets: 95295000 Open source Current Liabilities: 15804000 Open source
20192019-12-31	Current assets / current liabilities	1.18×	Current Assets: 111854000 Open source Current Liabilities: 94418000 Open source
20202020-12-31	Current assets / current liabilities	1.6×	Current Assets: 39443000 Open source Current Liabilities: 24701000 Open source
20212021-12-31	Current assets / current liabilities	7.32×	Current Assets: 49131000 Open source Current Liabilities: 6712000 Open source
20222022-12-31	Current assets / current liabilities	6.31×	Current Assets: 23801000 Open source Current Liabilities: 3772000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2013 2013-01-01 – 2013-12-31	−USD 7.97 million Exact value Exact value: -7969000 USD 2013-01-01 – 2013-12-31: -7969000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Bellicum Pharmaceuticals, Inc. · 2013-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Net Income: -7969000 USD Concept: fundies:NetIncome Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403/explain?concept=fundies%3ANetIncome&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:NetIncome: -7969000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000135840316000158/blcm-20151231.xml#276098 Filing: 000135840316000158 The citation records this snapshot. The page link may show a newer release later.	−USD 7.61 million Exact value Exact value: -7612000 USD 2013-01-01 – 2013-12-31: -7612000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Bellicum Pharmaceuticals, Inc. · 2013-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Operating Cash Flow: -7612000 USD Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -7612000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000135840316000158/blcm-20151231.xml#275463 Filing: 000135840316000158 The citation records this snapshot. The page link may show a newer release later.	USD 366,000 Exact value Exact value: 366000 USD 2013-01-01 – 2013-12-31: 366000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Bellicum Pharmaceuticals, Inc. · 2013-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Capital Expenditure: 366000 USD Concept: fundies:CapitalExpenditure Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403/explain?concept=fundies%3ACapitalExpenditure&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 366000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000135840316000158/blcm-20151231.xml#289288 Filing: 000135840316000158 The citation records this snapshot. The page link may show a newer release later.	−USD 7.98 million Calculation and evidence -7612000 − 366000 USD Exact free cash flow: -7978000 USD 2013-01-01 – 2013-12-31: -7612000 USD · Inspect Operating Cash Flow · Source 2013-01-01 – 2013-12-31: 366000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Bellicum Pharmaceuticals, Inc. · 2013-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Free cash flow: -7978000 USD Concept: free-cash-flow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -7612000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000135840316000158/blcm-20151231.xml#275463 Filing: 000135840316000158 Input fundies:CapitalExpenditure: 366000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000135840316000158/blcm-20151231.xml#289288 Filing: 000135840316000158 The citation records this snapshot. The page link may show a newer release later.
2014 2014-01-01 – 2014-12-31	−USD 83.97 million Exact value Exact value: -83965000 USD 2014-01-01 – 2014-12-31: -83965000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Bellicum Pharmaceuticals, Inc. · 2014-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Net Income: -83965000 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -83965000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000135840317000050/blcm-20161231.xml#280039 Filing: 000135840317000050 The citation records this snapshot. The page link may show a newer release later.	−USD 57.31 million Exact value Exact value: -57308000 USD 2014-01-01 – 2014-12-31: -57308000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Bellicum Pharmaceuticals, Inc. · 2014-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Operating Cash Flow: -57308000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -57308000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000135840317000050/blcm-20161231.xml#279403 Filing: 000135840317000050 The citation records this snapshot. The page link may show a newer release later.	USD 804,000 Exact value Exact value: 804000 USD 2014-01-01 – 2014-12-31: 804000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Bellicum Pharmaceuticals, Inc. · 2014-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Capital Expenditure: 804000 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 804000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000135840317000050/blcm-20161231.xml#293088 Filing: 000135840317000050 The citation records this snapshot. The page link may show a newer release later.	−USD 58.11 million Calculation and evidence -57308000 − 804000 USD Exact free cash flow: -58112000 USD 2014-01-01 – 2014-12-31: -57308000 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 804000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Bellicum Pharmaceuticals, Inc. · 2014-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Free cash flow: -58112000 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -57308000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000135840317000050/blcm-20161231.xml#279403 Filing: 000135840317000050 Input fundies:CapitalExpenditure: 804000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000135840317000050/blcm-20161231.xml#293088 Filing: 000135840317000050 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−USD 48.55 million Exact value Exact value: -48548000 USD 2015-01-01 – 2015-12-31: -48548000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Bellicum Pharmaceuticals, Inc. · 2015-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Net Income: -48548000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -48548000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000135840318000037/blcm-20171231.xml#250607 Filing: 000135840318000037 The citation records this snapshot. The page link may show a newer release later.	−USD 35.73 million Exact value Exact value: -35726000 USD 2015-01-01 – 2015-12-31: -35726000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Bellicum Pharmaceuticals, Inc. · 2015-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Operating Cash Flow: -35726000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -35726000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000135840318000037/blcm-20171231.xml#249971 Filing: 000135840318000037 The citation records this snapshot. The page link may show a newer release later.	USD 5.42 million Exact value Exact value: 5421000 USD 2015-01-01 – 2015-12-31: 5421000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Bellicum Pharmaceuticals, Inc. · 2015-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Capital Expenditure: 5421000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5421000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000135840318000037/blcm-20171231.xml#261684 Filing: 000135840318000037 The citation records this snapshot. The page link may show a newer release later.	−USD 41.15 million Calculation and evidence -35726000 − 5421000 USD Exact free cash flow: -41147000 USD 2015-01-01 – 2015-12-31: -35726000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 5421000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Bellicum Pharmaceuticals, Inc. · 2015-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Free cash flow: -41147000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -35726000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000135840318000037/blcm-20171231.xml#249971 Filing: 000135840318000037 Input fundies:CapitalExpenditure: 5421000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000135840318000037/blcm-20171231.xml#261684 Filing: 000135840318000037 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 69.24 million Exact value Exact value: -69241000 USD 2016-01-01 – 2016-12-31: -69241000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Bellicum Pharmaceuticals, Inc. · 2016-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Net Income: -69241000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -69241000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000135840318000037/blcm-20171231.xml#251377 Filing: 000135840318000037 The citation records this snapshot. The page link may show a newer release later.	−USD 50.44 million Exact value Exact value: -50441000 USD 2016-01-01 – 2016-12-31: -50441000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Bellicum Pharmaceuticals, Inc. · 2016-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Operating Cash Flow: -50441000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -50441000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000135840318000037/blcm-20171231.xml#250183 Filing: 000135840318000037 The citation records this snapshot. The page link may show a newer release later.	USD 7.22 million Exact value Exact value: 7220000 USD 2016-01-01 – 2016-12-31: 7220000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Bellicum Pharmaceuticals, Inc. · 2016-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Capital Expenditure: 7220000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 7220000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000135840318000037/blcm-20171231.xml#261894 Filing: 000135840318000037 The citation records this snapshot. The page link may show a newer release later.	−USD 57.66 million Calculation and evidence -50441000 − 7220000 USD Exact free cash flow: -57661000 USD 2016-01-01 – 2016-12-31: -50441000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 7220000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Bellicum Pharmaceuticals, Inc. · 2016-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Free cash flow: -57661000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -50441000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000135840318000037/blcm-20171231.xml#250183 Filing: 000135840318000037 Input fundies:CapitalExpenditure: 7220000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000135840318000037/blcm-20171231.xml#261894 Filing: 000135840318000037 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 91.78 million Exact value Exact value: -91779000 USD 2017-01-01 – 2017-12-31: -91779000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Bellicum Pharmaceuticals, Inc. · 2017-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Net Income: -91779000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -91779000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000135840319000038/blcm-20181231.xml#219657 Filing: 000135840319000038 The citation records this snapshot. The page link may show a newer release later.	−USD 72.98 million Exact value Exact value: -72984000 USD 2017-01-01 – 2017-12-31: -72984000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Bellicum Pharmaceuticals, Inc. · 2017-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Operating Cash Flow: -72984000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -72984000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000135840319000038/blcm-20181231.xml#218617 Filing: 000135840319000038 The citation records this snapshot. The page link may show a newer release later.	USD 12.13 million Exact value Exact value: 12134000 USD 2017-01-01 – 2017-12-31: 12134000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Bellicum Pharmaceuticals, Inc. · 2017-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Capital Expenditure: 12134000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 12134000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000135840319000038/blcm-20181231.xml#231299 Filing: 000135840319000038 The citation records this snapshot. The page link may show a newer release later.	−USD 85.12 million Calculation and evidence -72984000 − 12134000 USD Exact free cash flow: -85118000 USD 2017-01-01 – 2017-12-31: -72984000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 12134000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Bellicum Pharmaceuticals, Inc. · 2017-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Free cash flow: -85118000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -72984000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000135840319000038/blcm-20181231.xml#218617 Filing: 000135840319000038 Input fundies:CapitalExpenditure: 12134000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000135840319000038/blcm-20181231.xml#231299 Filing: 000135840319000038 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 98.04 million Exact value Exact value: -98036000 USD 2018-01-01 – 2018-12-31: -98036000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Bellicum Pharmaceuticals, Inc. · 2018-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Net Income: -98036000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -98036000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000135840320000007/blcm-20191231.xml#229065 Filing: 000135840320000007 The citation records this snapshot. The page link may show a newer release later.	−USD 74.78 million Exact value Exact value: -74782000 USD 2018-01-01 – 2018-12-31: -74782000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Bellicum Pharmaceuticals, Inc. · 2018-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Operating Cash Flow: -74782000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -74782000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000135840320000007/blcm-20191231.xml#228025 Filing: 000135840320000007 The citation records this snapshot. The page link may show a newer release later.	USD 1.62 million Exact value Exact value: 1617000 USD 2018-01-01 – 2018-12-31: 1617000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Bellicum Pharmaceuticals, Inc. · 2018-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Capital Expenditure: 1617000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1617000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000135840320000007/blcm-20191231.xml#241761 Filing: 000135840320000007 The citation records this snapshot. The page link may show a newer release later.	−USD 76.4 million Calculation and evidence -74782000 − 1617000 USD Exact free cash flow: -76399000 USD 2018-01-01 – 2018-12-31: -74782000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 1617000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Bellicum Pharmaceuticals, Inc. · 2018-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Free cash flow: -76399000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -74782000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000135840320000007/blcm-20191231.xml#228025 Filing: 000135840320000007 Input fundies:CapitalExpenditure: 1617000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000135840320000007/blcm-20191231.xml#241761 Filing: 000135840320000007 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 112.48 million Exact value Exact value: -112477000 USD 2019-01-01 – 2019-12-31: -112477000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Bellicum Pharmaceuticals, Inc. · 2019-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Net Income: -112477000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -112477000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000162828021006164/blcm-20201231.htm#1043931 Filing: 000162828021006164 The citation records this snapshot. The page link may show a newer release later.	−USD 77.57 million Exact value Exact value: -77569000 USD 2019-01-01 – 2019-12-31: -77569000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Bellicum Pharmaceuticals, Inc. · 2019-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Operating Cash Flow: -77569000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -77569000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000162828021006164/blcm-20201231.htm#1085214 Filing: 000162828021006164 The citation records this snapshot. The page link may show a newer release later.	USD 522,000 Exact value Exact value: 522000 USD 2019-01-01 – 2019-12-31: 522000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Bellicum Pharmaceuticals, Inc. · 2019-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Capital Expenditure: 522000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 522000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000162828021006164/blcm-20201231.htm#1092622 Filing: 000162828021006164 The citation records this snapshot. The page link may show a newer release later.	−USD 78.09 million Calculation and evidence -77569000 − 522000 USD Exact free cash flow: -78091000 USD 2019-01-01 – 2019-12-31: -77569000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 522000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Bellicum Pharmaceuticals, Inc. · 2019-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Free cash flow: -78091000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -77569000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000162828021006164/blcm-20201231.htm#1085214 Filing: 000162828021006164 Input fundies:CapitalExpenditure: 522000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000162828021006164/blcm-20201231.htm#1092622 Filing: 000162828021006164 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 7.72 million Exact value Exact value: -7722000 USD 2020-01-01 – 2020-12-31: -7722000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Bellicum Pharmaceuticals, Inc. · 2020-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Net Income: -7722000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -7722000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000162828022007196/blcm-20211231.htm#1012800 Filing: 000162828022007196 The citation records this snapshot. The page link may show a newer release later.	−USD 56.65 million Exact value Exact value: -56650000 USD 2020-01-01 – 2020-12-31: -56650000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Bellicum Pharmaceuticals, Inc. · 2020-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Operating Cash Flow: -56650000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -56650000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000162828022007196/blcm-20211231.htm#1045178 Filing: 000162828022007196 The citation records this snapshot. The page link may show a newer release later.	USD 625,000 Exact value Exact value: 625000 USD 2020-01-01 – 2020-12-31: 625000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Bellicum Pharmaceuticals, Inc. · 2020-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Capital Expenditure: 625000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 625000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000162828022007196/blcm-20211231.htm#1050242 Filing: 000162828022007196 The citation records this snapshot. The page link may show a newer release later.	−USD 57.28 million Calculation and evidence -56650000 − 625000 USD Exact free cash flow: -57275000 USD 2020-01-01 – 2020-12-31: -56650000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 625000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Bellicum Pharmaceuticals, Inc. · 2020-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Free cash flow: -57275000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -56650000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000162828022007196/blcm-20211231.htm#1045178 Filing: 000162828022007196 Input fundies:CapitalExpenditure: 625000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000162828022007196/blcm-20211231.htm#1050242 Filing: 000162828022007196 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 9.71 million Exact value Exact value: -9705000 USD 2021-01-01 – 2021-12-31: -9705000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Bellicum Pharmaceuticals, Inc. · 2021-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Net Income: -9705000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -9705000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000162828023010145/blcm-20221231.htm#792443 Filing: 000162828023010145 The citation records this snapshot. The page link may show a newer release later.	−USD 23.11 million Exact value Exact value: -23106000 USD 2021-01-01 – 2021-12-31: -23106000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Bellicum Pharmaceuticals, Inc. · 2021-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Operating Cash Flow: -23106000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -23106000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000162828023010145/blcm-20221231.htm#810765 Filing: 000162828023010145 The citation records this snapshot. The page link may show a newer release later.	USD 7,000 Exact value Exact value: 7000 USD 2021-01-01 – 2021-12-31: 7000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Bellicum Pharmaceuticals, Inc. · 2021-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Capital Expenditure: 7000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 7000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000162828023010145/blcm-20221231.htm#814482 Filing: 000162828023010145 The citation records this snapshot. The page link may show a newer release later.	−USD 23.11 million Calculation and evidence -23106000 − 7000 USD Exact free cash flow: -23113000 USD 2021-01-01 – 2021-12-31: -23106000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 7000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Bellicum Pharmaceuticals, Inc. · 2021-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Free cash flow: -23113000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -23106000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000162828023010145/blcm-20221231.htm#810765 Filing: 000162828023010145 Input fundies:CapitalExpenditure: 7000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000162828023010145/blcm-20221231.htm#814482 Filing: 000162828023010145 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 24.97 million Exact value Exact value: -24973000 USD 2022-01-01 – 2022-12-31: -24973000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Bellicum Pharmaceuticals, Inc. · 2022-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Net Income: -24973000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -24973000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000162828023010145/blcm-20221231.htm#791605 Filing: 000162828023010145 The citation records this snapshot. The page link may show a newer release later.	−USD 25.78 million Exact value Exact value: -25783000 USD 2022-01-01 – 2022-12-31: -25783000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Bellicum Pharmaceuticals, Inc. · 2022-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Operating Cash Flow: -25783000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -25783000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000162828023010145/blcm-20221231.htm#810046 Filing: 000162828023010145 The citation records this snapshot. The page link may show a newer release later.	USD 21,000 Exact value Exact value: 21000 USD 2022-01-01 – 2022-12-31: 21000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Bellicum Pharmaceuticals, Inc. · 2022-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Capital Expenditure: 21000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 21000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000162828023010145/blcm-20221231.htm#813863 Filing: 000162828023010145 The citation records this snapshot. The page link may show a newer release later.	−USD 25.8 million Calculation and evidence -25783000 − 21000 USD Exact free cash flow: -25804000 USD 2022-01-01 – 2022-12-31: -25783000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 21000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Bellicum Pharmaceuticals, Inc. · 2022-12-31 Bellicum Pharmaceuticals, Inc. (edgar:1358403) Free cash flow: -25804000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1358403?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -25783000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000162828023010145/blcm-20221231.htm#810046 Filing: 000162828023010145 Input fundies:CapitalExpenditure: 21000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1358403/000162828023010145/blcm-20221231.htm#813863 Filing: 000162828023010145 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

78 filings · 2,397 latest values · 2,397 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001358403, 1358403, BLCM, edgar:1358403

Also known as BELLICUM PHARMACEUTICALS INC, BELLICUM PHARMACEUTICALS, INC, BELLICUM PHARMACEUTICALS, INC., Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2022 2022-01-01 – 2022-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation